Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the 2017 Morgan Stanley Global Healthcare Conference on Wednesday, September 13, at 1:00 p.m. Eastern Time in New York City.
The presentation will be webcast live and available for replay on Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Michele Mantynen Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected]
